We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App




New Therapeutic Approach Floods Prostate Cancer Cells with Copper

By LabMedica International staff writers
Posted on 26 Oct 2014
Print article
A novel approach for treating prostate cancer is based on the co-administration of the drug disulfiram and copper, an element that the growing cancer cells require.

Serum copper levels have been found to be elevated in patients with prostate cancer, and increased copper uptake can be used as a means to image prostate tumors. It is unclear, however, to what extent copper is required for prostate cancer cell function as previous chelation strategies to treat the disease produced only modest effects on the growth of these cells in vitro.

In a paper published in the October 15, 2014, issue of the journal Cancer Research, investigators at Duke University (Durham, NC, USA) described screening libraries of thousands of approved drugs to identify those that rely on copper to achieve their results. Among the candidate compounds was disulfiram, a drug approved by the [US] Food and Drugs Administration to treat alcoholism. Disulfiram acts by inhibiting the enzyme acetaldehyde dehydrogenase, which slows the removal of acetaldehyde. Build-up of acetaldehyde causes vasomotor disturbances, nausea, vomiting, and even unconsciousness and death.

The investigators found that disulfiram alone had only a minimal effect on the growth of prostate cancer tumors propagated as xenografts in mice. However, when the drug was co-administered with copper, a very dramatic inhibition of tumor growth in models of hormone-sensitive and of castrate-resistant disease was observed. In addition, they determined that prostate cancer cells expressed high levels of CTR1, the primary copper transporter, and additional chaperones that were required to maintain intracellular copper homeostasis. The expression levels of most of these proteins were increased further upon treatment of androgen receptor (AR)–positive prostate cancer cell lines with androgens. Robust CTR1-dependent uptake of copper into prostate cancer cells was observed, an activity that was accentuated by activation of the androgen receptor.

"Our first efforts were to starve the tumors of copper, but that was unsuccessful. We could not deplete copper enough to be effective," said senior author Dr. Donald McDonnell, professor of pharmacology and cancer biology at Duke University. "So we thought if we cannot get the level low enough in cancer cells to kill them, how about we boost the copper and then use a drug that requires copper to be effective to attack the tumors. It is the old if-you-cannot-beat-them-join-them approach."

"Unfortunately, hormone therapies do not cure prostate cancer, and most patients experience relapse of their disease to a hormone-refractory or castration-resistant state," said Dr. McDonnell. "Although tremendous progress has been made in treating prostate cancer, there is clearly a need for different approaches, and our findings provide an exciting new avenue to explore. This proclivity for copper uptake is something we have known could be an Achilles' heel in prostate cancer tumors as well as other cancers."

Related Links:

Duke University


New
Gold Member
ANA & ENA Screening Assays
ANA and ENA Assays
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Serum Toxicology Benzodiazepine Assay
DRI Serum Toxicology Benzodiazepine Assay
New
Urine Collection Container
Urine Monovette

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: Schematic overview of maternal biomarker discovery using cell-free RNA during pregnancy (Photo courtesy of Circulation Research (2024). DOI: 10.1161/CIRCRESAHA.124.325024)

Maternal Blood Test Identifies Congenital Heart Diseases in Fetus

Each year, around 1,000 children are born with a single ventricle heart defect (SVHD), a condition where one of the heart's lower chambers is underdeveloped, too small, or missing a valve.... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Microbiology

view channel
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated... Read more

Pathology

view channel
Image

AI-Based Method Shows Promise for Pathological Diagnosis of Hereditary Kidney Diseases

Alport syndrome is a hereditary kidney disorder characterized by kidney dysfunction, sensorineural hearing loss, and ocular abnormalities. Early in the disease, patients experience hematuria, which is... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.